NCT Number: NCT00037440
Genetic Epidemiology of Change in CVD Risk Factors
To extend knowledge of the genetic factors affecting the course of cardiovascular disease risk factor development over a substantial portion of an individual's lifetime.
Looking for future studies?
Notify MeKey information
Conditions
Age range
8 year–38 year
Sex eligibility
All sexes
Study type
Observational
About this study
BACKGROUND:
While the onset of symptomatic cardiovascular disease (CVD) typically occurs in middle age or later, the development of the underlying pathology is clearly a long-term process, and early-state lesions having been identified at autopsy even in children. Understanding the course of CVD risk development from childhood into middle age will clearly be valuable both in understanding the pathology of CVD and in targeting preventive measures most effectively. Furthermore, while genetic factors are agreed to play a significant role in the development of CVD, most genes contributing to interindividual variation in CVD risk will have relatively small effects on risk for any given individual, even though their aggregate effects contribute significantly to CVD risk in the overall population. Relatively little is known about the effects of genetic variants on the course of CVD risk factor development in individuals over time. The Bogalusa Heart Study (BHS), which began in 1973 as a study of CVD risk factors in children but evolved to cover the development of CVD risk factors from childhood into early middle age, offers an unparalleled resource for investigating the genetic factors influencing within-individual changes over time in quantitative factors, such as serum lipids and blood pressure, related to CVD risk.
DESIGN NARRATIVE:
Approximately 1500 individuals who were examined in the BHS on at least three separate occasions over a period of up to 20 years, and who consented to participate in studies of genetic factors influencing CVD risk, will have genotypes measured at selected loci either known or strongly suspected to affect interindividual variation in CVD risk. Longitudinal multilevel regression will be used to measure the effects of variation at these loci on quantitative CVD risk factor profiles within individuals and to determine whether some gene effects on CVD risk variation are age-dependent.
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Schoolchildren from Bogalusa, Louisiana. All children in Bogalusa public schools were eligible.
Treatment and study plan
Primary outcomes
-
Plasma lipid levels
Time frame: Change from 8 - 18 years of age
Sponsors and collaborators
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
Registry information
Official study title
Genetic Epidemiology of Change in CVD Risk Factors (HL70568-1)
Important dates
- Study start
- 2001
- Primary completion
- 2005
- Study completion
- 2005
- First posted
- May 17, 2002
- Registry last updated
- Dec 3, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
CES1 Carriers in the PAPI Study
NCT03188705
Arterial Occlusive Diseases, Arteriosclerosis
Lancaster, Pennsylvania, United States
View Trial DetailsSoy Food and Coronary Heart Disease in Women
NCT00241735
Cardiovascular Diseases, Coronary Disease
View Trial DetailsHOLT-ED: Holter-monitoring in End-stage Renal Disease
NCT04876963
Arrhythmias, Cardiac, Cardiovascular Diseases
Copenhagen, Denmark
View Trial DetailsSapphire 3 CTO Study
NCT06358508
Arterial Occlusive Diseases, Arteriosclerosis
Stanford, California, United States
View Trial Details